We were delighted to speak to Laure Gossec (Sorbonne Université and Pitié-Salpétrière Hospital, Paris, France) about the 48-week results of the BE ACTIVE phase 2b study of bimekizumab in psoriatic arthritis (Clinical Trial Identifier: NCT02969525). The abstract ‘Bimekizumab Improves Patient-Reported Outcomes in Psoriatic Arthritis: 48-Week Results from a Phase 2b Study and Association Between Patient-Reported Outcomes and Disease Activity‘ (ABSTRACT NUMBER: 0356) was presented at the virtual ACR Convergence 2020, 5-9 November 2020.
- Could you tell us a little about bimekizumab and its mechanism of action? (0:15)
- Why are patient-reported outcomes (PROs) important and what are the most useful PROs in psoriatic arthritis? (0:37)
- Could you tell us a little about the BE ACTIVE study? (1:25)
- What were the major findings of the BE ACTIVE study? (2:09)
- How well did the PROs correlate with disease activity, and what are the implications of these findings for clinical practice? (3:07)
Disclosures: Research grants: Amgen, Galapagos, Janssen, Lilly, Pfizer, Sandoz, Sanofi; consulting fees: AbbVie, Amgen, BMS, Biogen, Celgene, Gilead, Janssen, Lilly, Novartis, Pfizer, Samsung Bioepis, Sanofi-Aventis, UCB.
Support: Interview and filming supported by Touch Medical Media.
Filmed in coverage of the ACR Convergence 2020 (Virtual).
Share this Video
Related Videos In Psoriatic Arthritis
Laura Coates, ACR 2020 – Results from the FUTURE 5 Study
We caught up with Laura Coates (University of Oxford, Oxford, UK) to discuss the results from FUTURE 5, the phase 3 study of secukinumab in patients with psoriatic arthritis (Clinical Trial Identifier: NCT02404350). The abstract ‘Achievement of Sustained Remission and Low Disease Activity with Secukinumab Improves Quality of Life and Physical Function in Patients with […]
Christopher Ritchlin, ACR 2020 – Results from the DISCOVER-1 Phase 3 Trial
We were delighted to speak to Christopher Ritchlin (University of Rochester, Henrietta, NY, USA) about the one year results from the DISCOVER-1 Phase 3 trial of guselkumab in active psoriatic arthritis (Clinical Trial Identification: NCT03162796). The abstract ‘Guselkumab, an IL-23 Inhibitor That Specifically Binds to the IL23p19-Subunit, for Active Psoriatic Arthritis: One Year Results of […]
Deepak Jadon, ACR 2020 – Psoriatic Arthritis Research Highlights 2020
It was a pleasure to speak to Deepak Jadon (Cambridge University Hospitals, Cambridge, UK) about his research highlights from this year in the field of psoriatic arthritis (PsA) and his highlights from the annual ACR Convergence meeting. Questions What have been the most notable research articles published in PsA this year? (0:05) What were the […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!